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Background: Approximately 25% of so-called high utilizers of medical care are estimated to suffer from depression.
A large proportion of these individuals remain undiagnosed and untreated. This study aims to examine the effects
of a systematic screening and collaborative treatment program on depression severity in small primary care
practices of the German outpatient health care system.
Method: High utilizers of primary care who screened positive for depressive symptoms on the Brief Psychiatric
Health Questionnaire (B-PHQ) were further diagnosed using the DIA-X, a standardized diagnostic interview,
performed by trained and supervised interviewers. Patients with major depression were randomized (cluster
randomization by practice) to (a) a six-month treatment program of pharmacotherapy, standardized patient and
provider education, and physician and patient counseling or (b) six months of usual medical care. All subjects were
followed for a 12-month observation period using the 17-item Hamilton Depression Rating scale (HAMD-17) rated
by the treating physicians and the B-PHQ-9 rated by the patients.
Results: A total of 63 high utilizer patients were included in the trial (17 male, 46 female), 19 randomized to
intervention, 44 to usual care. The mean age was 49.7 (SD 13.8). Most patients had one or more somatic
co-morbidities. There was no significant difference in response (defined as a decrease in the HAMD-17 sum score
of at least 50%) after six months of treatment (50% vs. 42%, p = 0.961, all analyses adjusted for age) and after
12 months of treatment (83% vs. 54%, p = 0.282) between groups. Using patient self-rating assessments with the
B-PHQ-9 questionnaire the intervention was superior to treatment as usual at six months (83% vs. 16%, p = 0.000).
There was no significant difference in HAMD-17 depression severity at six months between the groups (10.5 (SD
7.6) vs. 12.3 (SD 7.8), p = 0.718), but a trend at 12 months (4.7 (SD 8.0) vs. 11.2 (SD 7.4), p = 0.083). Again, using
B-PHQ-9 sum scores depression severity was significantly lower in the intervention group than in the treatment as
usual group after six months (6.4 (SD 5.2) vs. 11.5 (SD 5.8), p = 0.020), but not at 12 months (7.9 (SD 8.7) vs. 9.0
(SD 5.2), p = 0.858).
Conclusion: A systematic collaborating treatment program for depression in high utilizers in primary care
showed superiority to treatment as usual only in terms of patients´ self-assessment but not according to
physicians´ assessment. The advance of the intervention group at 6 months was lost after 12 months of
follow-up. Overall, positive results from similar trials in the US health care systems could not be confirmed in a
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Depression is regarded as one of the leading causes of
disability worldwide [1]. Within the World Mental
Health Survey Initiative a 12-month prevalence of major
depressive disorders of 5.5% in high-income countries
and 5.9% in middle and low income countries was
reported [2]. The pan-European survey of depression
across six countries DEPRES detected a 6-month preva-
lence of 17% [3]. The more recent ESEMeD project
reported a lifetime prevalence of major depression of
12.8% [4]. Comparable prevalence rates for depression
were found by the German National Health Interview
and Examination Survey (GHS), a government mandated
nationwide study including a random sample drawn
from population registries [5].
Those seeking help mostly consult facilities in primary
care. However, depression in primary care is often over-
looked and severely undertreated. DEPRES II demon-
strated that 70% of depressed patients had received no
antidepressant therapy during their most recent depres-
sive episode [6,7]. In the German GHS sample, only ap-
proximately 50% of patients with any depressive disorder
received at least minimal intervention [5]. The Depres-
sion 2000 study, which included 20,421 patients in 633
primary care practices, detected a point prevalence of
depression of 11% in German primary care practices.
Physicians recognized 59% of all ICD 10 depression
diagnoses correctly, however, false diagnoses were given
in 11.7% [8].
Unrecognized or undertreated depression is especially
problematic in patients who make frequent use of
healthcare services and are commonly referred to as
“high utilizers” in health-systems research. Depression is
thought to increase the use of medical care [9], and ap-
proximately 25% of high utilizers are estimated to suffer
from depression [10,11].
With these figures in mind, primary care-based man-
agement programs would seem useful in improving the
care of depressed patients, and have been proposed by
a range of international experts [12,13]. Modern care-
management programs are multifaceted and generally
incorporate a systematic approach to treatment
(e.g. evidence-based practice guidelines or algorithm-
guided treatment regimens); patient and family educa-
tion programs; practice reorganization to meet the
needs of chronically ill patients; and available expert
consultation for practitioners and staff, and care-
manager for tracking patient’s visits and enhancing
compliance. More than 40 studies have proven the effi-
cacy of various combinations of these facets during the
last 2 decades [14-17].
Several of these studies focus on applying treatment
algorithms within inpatient and/or outpatient psychiatric
settings, e.g. Texas Medication Algorithm Project,TMAP [18], German Algorithm Project, GAP [19], both
in psychiatric settings, and Sequenced Treatment Alter-
natives to Relieve Depression STAR*D in primary care
[20], (see [21] for a comprehensive review).
Only a few studies of collaborative care have included
a systematic treatment algorithm for depression in pri-
mary care. The IMPACT (Improving Mood: Promoting
Access to Collaborative Treatment) trial [22-24] and the
PROSPECT study [25] focused on elderly and geriatric
patients. The trial of Ijff et al was conducted in the
Netherlands, combining multifaceted collaborative care
elements in small primary care practices [26]. Controlled
studies on depression care management programs
designed specifically to optimize the treatment of de-
pression in high utilizers are rare [27].
Most of the collaborative care studies were per-
formed in the US within health plans, large primary
care clinics or in collaboration with large insurance
funds, which allowed for providing additional staff for
care management and resorting to existing coordinating
structures. Other studies were performed within the
UK health system, a national health system with top
down regulation and primary care system with gate
keeping function.
The results cannot be easily transferred to the German
health system. Outpatient care is delivered by physicians
working alone or in small cooperatives, primary care
practices generally do not have gatekeeper function. The
previous fee-for-service reimbursement has increasingly
been replaced by lump-sums for various basic services
and is capped. Incentives for collaboration and improv-
ing quality of care are lacking [28].
The only controlled trial on collaborative primary
care in Germany performed by Gensichen and cowor-
kers showed superiority of a systematic screening and
monitoring of patients for depression and a care man-
agement with regular telephone contacts by trained
practice staff (PRoMPT) in reducing depression
symptoms [29].
While the physicians in PRoMPT were free with re-
gard to their treatment decisions, we conducted a study
which combined an antidepressant treatment algorithm
with a collaborative care concept including systematic
screening, monitoring and care management by practice
staff as well as expert supervision and assistance with re-
ferral which can be implemented within the German
outpatient health care system.
Methods
A total of 31 primary care physicians in Berlin and
Brandenburg participated in the present study which
was performed between 2004 and 2005. Primary care
practices were assigned randomly to implement a sys-
tematic depression-management program or to provide
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subsequent follow-up period of six months. The study
design is illustrated in Figure 1.
Inclusion and exclusion criteria
To be included in the study, patients had to:
(1) be classified as a high utilizer of healthcare
(≥5 visits to any physician within the most recent
completed quarter of the year, including physician
and patient initiated appointments)
(2) screen positive for depression (i.e. have at least four
positive answers on the Brief Patient Health
Questionnaire (B-PHQ) including the symptom of
feeling down and/or little interest or pleasure in
doing things)
(3) be diagnosed with unipolar depressive disorder and
be experiencing a major depressive episode of at
least moderate severity according to the Diagnostic
Expert System for Psychiatric Disorders (DIA-X)Figure 1 Study design of screening and randomized treatment of pat
Health Questionnaire, DIA-X = Diagnostic Expert System for Psychiatr
Global Impression Scale, CGI-CS = Clinical Global Impression Change(4) be at least 18 years old
(5) have sufficient cognitive ability and language skills
to participate in the study
(6) and provide written, informed consent.
Patients were excluded from participation in the study
if they
(1) had already received treatment for their current
depressive episode with antidepressants or formal
psychotherapy
(2) were currently experiencing a minor depressive
episode according to the DIA-X
(3) were diagnosed with a psychiatric disorder other
than unipolar depressive disorder (e.g. bipolar
disorder, schizophrenia, schizoaffective disorder,
alcohol and/or drug dependence)
(4) exhibited suicidal behavior on more than half of the
days during the two weeks before the day on which
they completed the B-PHQ (item on the B-PHQ)ients with depression in primary care (B-PHQ = Brief Patient
ic Disorders, HAMD = Hamilton Depression Scale, CGI = Clinical
Score, SER = Sertralin, DOX = Doxepine).
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(6) or were judged by the attending physician to be
unable to participate due to severe medical illness.
Randomization
Practices who agreed to participate in the study were
assigned using computer-based randomization in the
study coordinating center either to the intervention arm
or to the treatment as usual arm. Patient random assign-
ment status was nested within the practice status. Prac-
tice staff was not blinded to the allocation to a group
due to the necessary training in the intervention group,
however, treatment as usual practices did not have
access to the provided intervention plan.
Sample recruitment
High utilizers of healthcare services were identified by
staff members in each study practice using either their
computerized patient documentation system or the
questionnaire employed to screen patients for participa-
tion in the study. Subsequently, patients were evaluated
for depression using the B-PHQ, a short self-report in-
strument extracted from the PRIME-MD Patient Health
Questionnaire [30,31]. With a cut-off of at least four
positive answers including the cores symptoms, sensitiv-
ity is 71% and specificity 91% [32]. High utilizers who
screened positive for depression were asked for informed
consent by their attending physician. After providing
written informed consent, patients’ contact data were
transmitted to the study coordinating center. Diagnoses
were validated at the coordinating center by trained and
supervised interviewers using the DIA-X, a standardized
diagnostic telephone interview [33-35]. If the patient
met all inclusion criteria the coordinating center
informed the attending primary care physicians to initi-
ate the first study visit; if the patient was excluded, a
consulting psychiatrist (AP) at the coordinating center
made recommendations regarding patient referrals (e.g.
to a private-practice psychiatrist or a hospital).
Intervention program
The intervention program included three categories of
interventions: (1) Elements focusing on the primary care
practice, (2) elements focusing on the participating phy-
sicians, and (3) elements focusing on patients and lasted
six months followed by a follow up period of another six
months. During the second six months physicians could
either continue the treatment according to the system-
atic depression-management program or change to any
other treatment or stop treatment.
The primary care practice was provided with a treat-
ment algorithm applying an antidepressant (sertraline or
in case of insufficient efficacy or intolerability, doxepine)
and received simple and efficient instruments to assessdepression severity and course (B-PHQ). In addition, the
office staff was trained in using the intervention program
and applying the case management via telephone. The
participating physicians were informed and trained in
using the instruments and applying the intervention pro-
gram and received a compact information brochure. At
any time they had access to a telephone hotline staffed
by a psychiatric consultant to help answer any questions
the primary care physicians might have.
The patients received an information brochure meet-
ing the needs of the patients and their relatives. The ma-
terial included information about causes, symptoms and
course of depression, step by step self-help recommen-
dations which should encourage patients to participate
in activities. Patients’ feedback regarding the recommen-
dations in the brochure were not included in the study.
The antidepressant treatment algorithm was per-
formed as shown in Figure 1. Insufficient response was
defined as a CGI change of condition score < 4. In case
of nonresponse or intolerance to doxepine the patient
left the study and was referred to a mental health spe-
cialist. Sertraline was provided to the primary care phys-
ician free of charge for up to six months; doxepine had
to be prescribed according to standard billing proce-
dures. Doxepine was chosen to ensure that second-line
treatment would involve an antidepressant with a differ-
ent mechanism of action. Moreover, doxepine is well
known to primary care physicians in Germany and does
not overextend their limited budget for prescription
medication.
Case-management consisted of structured telephone
calls with the patient conducted by a trained staff mem-
ber from the primary care practice. During the calls,
patients were asked if they had a sufficient supply of
medication and if they had experienced any side effects.
Patients were also reminded about their next visit to the
primary care practice. The calls were planned to last for
approximately five to ten minutes each and were per-
formed by the same practice staff member.
Treatment as usual
Physicians who were randomized to the non-
intervention group were asked to treat their patients as
they normally would do for this diagnosis. The physi-
cians in this group were free to choose any treatment
they felt was necessary during the first six months. Dur-
ing the follow-up period of months seven to 12 they
could either continue or stop their treatment as usual.
Assessment instruments and endpoints
Participating patients were assessed at the beginning of
the study and after three, six, nine, and 12 months. In
the intervention arm, patients were seen additionally
every two weeks following study entry until the optimal
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instruments used were the B-PHQ, Clinical Global
Impressions (CGI) [36], and Hamilton Depression Rat-
ing Scale (HAM-D, 17-item version [37], the last being
guided by a structured interview [38]. Additionally, the
CRF included questions on comorbid somatic illnesses,
use of medications (including non-psychotropic’s), and
the use of healthcare services. All visits and assessments
were performed by the treating physician in order to
avoid any interrater variation in the assessment or dis-
ruption in the treatment process.
The primary endpoint was the response (defined as a
decrease in the HAMD-17 sum score of at least 50%) in
physicians’ assessment after 6 months of treatment.
Secondary endpoints were the response in physicians’
assessment after 12 months of treatment, the response
(defined as a decrease in the sum score of at least 50%)
in patient self-assessment with the B-PHQ-9 question-
naire after 6 and 12 months, and the depression severity
measured by both the HAMD-17 and the B-PHQ-9 after
6 and 12 months.
Sample size calculation
The sample size calculation was based on results of
studies of sertraline in primary care (e.g. [39]). It was
assumed that 80% of patients in the intervention group
would respond according to the HAMD after six months
to treatment with sertraline and 50% would respond to
treatment as usual after 6 months in the non-
intervention arm of the study. With the alpha error set
at 0.05 and the beta error at 0.2, the sample size was
projected to be 37 patients per group (i.e. a total of 74
patients). The difference in the percentage of responders
was tested using a one-sided chi-square test.
Because of the cluster-randomization (not patients but
practices will be randomized), the sample size was
adjusted using a variance inflation factor. With 15 clus-
ters including five patients each (in total 75 patients)
and a variance inflation factor of 1.16 a sample size of 88
will be needed.
Analysis
All analyses were based on an intention-to-treat ap-
proach. Apart from complete subject analysis, analyses
with missing data replaced by last observation carried
forward (LOCF) were done. Comparability of the groups
at baseline was assessed using t tests and chi-square
tests. To identify influencing variables, linear regression
analyses with age, gender, education, treatment group,
and depression severity at baseline were used. One-sided
chi-square-test and ordinal regression analysis (including
influencing variables at baseline as covariates) were used
to analyze categorical data, ANCOVA were applied to
analyze group differences of metric data includingvariables different between the groups at baseline as cov-
ariates. ANCOVA for repeated measurements were used
to investigate differences in the course of treatment from
baseline over three, six, nine, and 12 months between
the groups, again including variables differing between
the groups at baseline as covariates.
The study protocol was approved by the local Univer-
sity Ethics Board (Charité - Universitätsmedizin Berlin,
Germany) and adheres to the Declaration of Helsinki.
All patients gave written informed consent before par-
ticipating in the study.
Results
Baseline characteristics of the patients
A total of 129 high utilizers were screened positive with
depressive symptoms. Of these, 63 patients were
included in the study. Various reasons for exclusion and
baseline characteristics of the patient sample are
reported in Table 1. Most of the study patients were of
working age; a substantial proportion was unemployed
and had a household income equivalent of lower than
US$ 1000. A large percentage of patients had a somatic
comorbidity and were on sick leave. The intervention
and usual-treatment groups differed only with respect to
age, therefore statistical analyses were adjusted for age.
Twenty of the patients in the as usual treatment arm
(45.5%) received psychopharmacological therapy (one
with amitriptyline, eight with an SSRI, five with mirtaze-
pine, one with a combination of amitriptyline and mirta-
zepine, one with a combination of trimipramine and
opipramol, one with venlafaxine, and four with St. John’s
wort). In the seven patients who were treated with psy-
chotherapy, five also received antidepressants. Fifteen
patients (34.1%) did not receive any antidepressive treat-
ment. For six patients in the usual treatment arm, no
treatment information was available.
Thirteen of the patients in the intervention arm of the
study were treated with sertraline (68.4%). One patient
was treated with doxepine (in addition to psychother-
apy). Two patients did not receive any antidepressive
treatment. No treatment information was available for
three patients in the intervention arm.
Study endpoints
After six months as well as after 12 months of treatment
both patients in the intervention and in the treatment as
usual group showed response but groups did not differ
according to physicians’ assessment (see Table 2). Re-
placing missings with LOCF did not change the results.
The effect size for response after 6 months was 1.4 (0.4 -
5.1), after 12 months 4.2 (0.4 - 39.9).
Depression severity as evaluated by physicians using
the HAMD-17 scale at six months did not differ be-
tween the groups. At 12 months depression severity in
Table 1 Baseline characteristics of the patients included in trial
High utilizer screened with major depression in the B-PHQ 129
• DIA-X negative for psychiatric disorder 7
• Other non-affective disorder (psychosis, somatisation, etc.) 11
• DIA-X positive for unipolar major depression and study entry 63
• Excluded from study participation 48
- depressive episode already remitted or treated 10
- dysthymia 15
- inadequate cognitive or language ability to complete questionnaires 4
- withdrawal of informed consent 1
- severe suicidal ideation 18
Intervention n= 19 Treatment as usual n = 44 p-value
Age (years, mean ± SD) 44.5 ± 12.0 51.9 ± 14.0 0.048
Gender (% male) 21 30 0.552
Education 0.737
- % no degree 12 5
- % elementary school 29 28
- % secondary school 35 35
- % A-levels 18 15
- % university degree 6 18
Work status 0.787
- % on sick leave 47 55
- % unemployed 26 20
- % retired 16 18
% with household income equivalent <US$ 1000 42 32 0.553
Depression severity (HAMD sum score, mean ± SD) 20.6 ± 4.4 18.5 ± 6.5 0.247
Self-rated depression (B-PHQ sum score, mean ± SD) 17.6 ± 4.4 16.0 ± 3.7 0.089
% with somatic comorbidity
- cardiovascular disease 84 61 0.934
- diabetes 11 9 0.843
- chronic pain syndrome 63 50 0.272
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usual treatment group as measured using the HAMD-17
scale. However, at all time points after baseline the
scores were numerically lower in the intervention group.
Replacing missing data by the last observation did not
change the results.
Using patients’ self assessment with the BPHQ-9 ques-
tionnaire the intervention group yielded superior results
(at least 50% reduction of the baseline BPHQ-9 sum
score) after six months of treatment but not at
12 months (see Table 2). Replacing missing data by the
last observation did not change results. The effect size
for response after 6 months was 27.0 (4.5 - 162.2), after
12 months 2.3 (0.4 - 14.2).
When analyzing the sum scores for self-rated depres-
sion using the B-PHQ-9, patients had significantly lower
sum scores in the intervention group than in the asusual group at six months. However, at 12 months no
significant difference between the groups could be
observed (see Table 2). Again, at all time points after
baseline the scores were numerically lower in the inter-
vention group.
When replacing missing data by the last observation
the difference at six months was not any longer statisti-
cally significant. Without replacement, there was no dif-
ference in the score at 12 months.
Discussion
In the present study, a substantial number of patients
classified as high utilizers of healthcare services and
diagnosed with major depression could be recruited for
antidepressant treatment. The systematic depression-
management program was shown to be superior to
treatment as usual in primary care after 6 months
Table 2 Treatment response (defined as 50% change from baseline sum score) in physicians’ assessment using
HAMD-17 item scale and by patients’ self-assessment using B-PHQ 9 questionnaire, and HAMD-17 sum scores and
B-PHQ 9 sum scores at 6 month and at 12 month in the intervention group and in the group treated as usual, all
analyses adjusted for age
Intervention Treatment as usual p-value
Physicians’ assessment
Response in HAMD-17 score at 6 months (n, %), n = 45 6 (50) 14 (42) 0.961
Missing values replaced by LOCF, n = 57 6 (38) 15 (37) 0.756
Response in HAMD-17 score at 12 months (n, %), n = 41 5 (83) 19 (54) 0.282
Missing values replaced by LOCF, n = 59 6 (38) 20 (47) 0.388
Depression severity by HAMD-17 score at 6 months (mean, SD), n = 45 10.5 (7.6) 12.3 (7.8) 0.718
Missing values replaced by LOCF, n = 58 12.8 (7.7) 13.8 (8.3) 0.954
Depression severity by HAMD-17 score at 12 months (mean, SD), n = 41 4.7 (8.0) 11.2 (7.4) 0.083
Missing values replaced by LOCF, n = 60 11.5 (8.1) 12.8 (8.2) 0.847
Patients’ self assessment
Response in B-PHQ 9 score at 6 months (n, %), n = 44 10 (83) 5 (16) 0.000
Missing values replaced by LOCF, n = 60 10 (56) 7 (17) 0.002
Response in B-PHQ 9 score at 12 months (n, %), n = 38 4 (67) 15 (47) 0.346
Missing values replaced by LOCF, n = 60 7 (37) 19 (43) 0.887
Depression severity by B-PHQ 9 score at 6 months (mean, SD), n = 45 6.4 (5.2) 11.5 (5.8) 0.020
Missing values replaced by LOCF, n = 60 9.8 (6.9) 11.7 (5.4) 0.375
Depression severity by B-PHQ 9 score at 12 months (mean, SD), n = 42 7.9 (8.7) 9.0 (5.2) 0.858
Missing values replaced by LOCF, n = 60 10.6 (7.5) 9.6 (5.1) 0.428
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severity of depression at six months measured by physi-
cians’ assessment using the HAMD scale – the primary
endpoint of the study – did not differ between the two
groups. In short, the depression-management program
was superior only with respect to the secondary end-
point patient self-assessment.
Our study differed in so far from various other con-
trolled trials of multifaceted interventions to improve
depression in primary care in that we used a formal
medication algorithm which facilitates the prescription
of antidepressant medication for the primary care phys-
ician. Against the background of an extensive range of
antidepressant products and complex recommendations
on dose and length of treatment this might have lowered
the threshold to treat depression in primary care. In
addition, our intervention plan was designed to use
existing primary care office staff as opposed to most pri-
mary care collaborative care trials that introduced men-
tal health trained staff into the office. Using primary care
office staff on the one hand facilitated the long-term im-
plementation of multifaceted interventions after the clin-
ical trial had stopped. On the other hand, this reflected
the routine conditions in primary care more appropri-
ately and enhanced the external validity of the results.
Our study was performed in small primary care prac-
tices which are typical for the German outpatient healthcare system, not possessing routine pathways for referral
and networking and leading to substantial waiting time
when referring to a specialist. In this regard our study
was designed to be feasible for routine primary care.
Fourthly, this study focused on high utilizers who rep-
resent a high risk group for depressive symptoms and
thus mean a substantial economic burden for the health
care system.
Compared to the large collaborative care trials in the
UK and U.S. [14-17] the difference in response to de-
pression treatment between intervention and usual care
was modest. The outcome of the intervention group was
not persistently superior to usual care. The findings of
our study have to be evaluated with several limiting fac-
tors kept in mind. Firstly, the number of patients ultim-
ately included in the study did not reach the number
projected in the sample size calculation. As a result, the
study was slightly underpowered despite the various
measures that were taken to encourage the recruitment
of study patients. The number of primary care physi-
cians invited for participation in the study was increased
during the recruitment period to the final number of
1,725 physicians in Berlin and surroundings in order to
find more study sites. Of these, only 62 physicians agreed
to participate in the study. Because some primary care
physicians were not able to identify high utilizers using
their particular computerized patient documentation
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asking the patients themselves. Because most practices
had difficulties screening patients with the provided ma-
terial, screening was conducted by trained doctoral stu-
dents. The reimbursement to the study sites for screening
more patients was increased. By this means we tried to
increase the number of patients which were eligible for
study entry.
The data suggest that there were quite substantial dif-
ferences in scores that persist over the course of the
study. We assume that if the study would have had suffi-
cient power, there would likely have been clinical and
also statistical significant differences between both
groups.
Secondly, patients in the intervention arm showed vari-
ous divergences from the study design. Only two-thirds of
the 19 patients included in the study were in fact treated
with sertraline, the first-choice drug in our systematic
disease-manage program. One patient received doxepine
due to intolerance to sertraline, and five patients did not
receive any pharmacological treatment or data were miss-
ing due to a lack of documentation in the primary care
practice. In the treatment-as-usual group, approximately
half of the patients received some form of antidepressant
treatment. We were surprised about the high rate of
treatment in usual care and the range of treatments used.
However, with the treatment-as-usual arm not being as
undertreated as we had expected, the difference between
the percentage of treated patients in the two study arms
became small.
Thirdly, the intervention group and the usual-
treatment group were of different size. This was due
to the necessary randomization of physician practices
as a whole rather than single patients. The latter was
not possible because patients randomized to different
study arms within the same practice would have lead
to contamination of treatment effect. Indeed cluster
randomization was practiced in nearly all of the collab-
orative care trials. During the study some physicians
were more active in recruiting patients, which ultim-
ately resulted in different group sizes.
We used doxepine as the antidepressant of second
choice for two reasons. Firstly, if during the treatment
period sertraline had to be stopped due to adverse
events or nonresponsive, the treating physician should
have been able to change to an antidepressant which
has a different mechanism of antidepressive action. Al-
though the switch from one antidepressant to another
in non responders is discussed controversially there is
evidence for switching from an SSRI to a tricyclic drug
[40,41]. Secondly, doxepine is a well known antidepres-
sant in primary care in Germany and does not burden
the limited budget of the GPs for prescriptions which
is around 15 Euro per patient per month in the regionof the study sites. The comparably expensive sertraline
was distributed as a study medication for free, whereas
the switch medication had to be prescribed by the
physician. In order to avoid early treatment termin-
ation of sertraline due to the low prescription cap in
practices this model was chosen.
The study did not include a follow-up of non respon-
ders after leaving the treatment plan. Patients and pri-
mary care physicians have freedom to choose a specialist
for referral in the German health care system. Contract-
ing new study sites during the ongoing study would have
been unfeasible.
The systematic treatment plan provided the Clinical
Global Impression Scale for diagnosing partial or nonre-
sponsive during the treatment period. This comparably
rough instrument was chosen to facilitate the study con-
ditions for the GPs as far as possible. Using the HAMD
scale as a basis for treatment decisions would have over-
strained the willingness of the GP to participate in the
study. On the other hand, using the CGI as a basis for
treatment decisions might have been an inaccurate and
imprecise approach and would have lead to early
switches from sertraline to doxepine or to early fixation
of the antidepressant dose. In addition, the assessment
of depression severity using the HAMD and the CGI
was done by the treating physician himself or herself
and not by independent raters blind to the intervention
status.
The discrepancy between the results measured by phy-
sicians’ rating using the HAMD-17 scale and the
patients’ self rating with the B-PHQ-9 questionnaire is
striking. This may have simply been the effect of the
small sample size. However, although the HAMD scale
served as the gold standard, it may have had limited
feasibility in primary care due to its length and the lee-
way which is given to the raters to score the patients’
answers. We applied the HAMD scale together with a
standardized interview and a comprehensive guideline
for scoring, and physicians performed a rater training
before study start. Not all physicians might have used
the material properly or pressure of time in routine care
might have hampered the proper application.
Self-rating measures were used as a primary outcome
in many of the large collaborative care studies [22,42,43]
and have been shown to provide valid ratings in non-
psychotic depressed outpatients [44]. The B-PHQ-9 has
been proven as a valid instrument for measuring treat-
ment efficacy and the standard definition of improve-
ment agreed sufficiently with other definitions of
patients’ improvement [45,46]. Based on the B-PHQ-9
scores our study results were comparable to those of
other collaborative care trials.
While most of the larger trials were using additional
staff for care-management, embedding additional
Berghöfer et al. BMC Health Services Research 2012, 12:298 Page 9 of 10
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with more complex medication algorithms, which might
not work without additional funding or support by aca-
demic centers, our systematic depression management
program was mainly designed to fit into routine primary
care in the German outpatient health care system, based
on using the available resources and being appropriate
for long-term use. However, the adherence to the medi-
cation algorithm was not complete and frequency of
using the supervision by psychiatric experts was
altogether low. Embedded in daily routine of the primary
care practice doctors might have been overstrained by
the management program.
A number of barriers to adequate depression manage-
ment in Germany have been discussed in the existing lit-
erature, and several of them may help explain the
experiences described in this study. These include
system-level barriers, such as practice organization, the
fiscal separation of physical and psychiatric services by
the Regional Associations of Social Health Insurance-
accredited Physicians, and the subsequent lack of add-
itional reimbursement for the increased costs associated
with the care of psychiatric patients [47]. We tried to
compensate by reimbursing the additional time spent on
treating psychiatric patients. However, our financial
resources were not enough to provide sufficient
incentive.
Conclusion
The study has shown moderate superiority of a system-
atic depression treatment and management program
over a treatment as usual in primary care only from the
patients’ perspective. The study gives limited indication
that the utilization of systematic treatment plans for psy-
chiatric disorders in small primary care practices in the
German health system seems feasible and effective.
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